The Positive and Negative Syndrome Scale for Schizophrenia Autism Severity Scale (PAUSS) in a sample of early-onset psychosis

Introduction The Positive and Negative Syndrome Scale for Schizophrenia Autism Severity (PAUSS) scale can be derived from the Scale, enabling an assessment of psychotic autistic dimensions with a single tool. Objectives aim study was to investigate prevalence traits diagnostic, developmental, clinical, functional correlates this phenotype in sample early-onset psychosis (onset before age 18 years; EOP). Methods Prospective observational 2 year- follow-up young people first-episode EOP. Demographic, perinatal, cognitive, data were collected. PAUSS total scores socio-communication repetitive behaviors subscores calculated. We used proposed cut-off points adult populations define (PAUSS≥30). Subgroups patients without identified based on terciles. Cronbach’s alpha test assess internal consistency. Linear mixed models performed compare changes during between diagnostic subgroups [i.e., non-affective (including schizophrenia schizophreniform disorder), affective bipolar disorder, schizoaffective disorder major depressive features), other brief not otherwise specified)]. Developmental, variables compared logistic regression analysis. Results 248 PIT included (age 15.69 ± 1.86 years, 38.65% female). EOP 7.04%, significantly higher group (15.20%) than groups. decreased over time, no significant differences trajectories its among three 2-year follow-up. showed good consistency at all visits (Cronbach’s > 0,88). Patients presented longer duration untreated psychosis, first inpatient admission, poorer social adjustment childhood, functionality, greater clinical severity, response treatment traits. Conclusions is easy-to-apply tool that useful differentiate worse prognosis. Disclosure Interest J. Suárez Campayo: None Declared, L. Pina-Camacho: Merchán-Naranjo: C. Ordas: V. Cavone: R. Panadero: G. Sugranyes: I. Baeza: Castro-Fornieles: E. de la Serna: Arango Consultant of: Acadia, Angelini, Gedeon Richter, Janssen Cilag, Lundbeck, Minerva, Otsuka, Roche, Sage, Servier, Shire, Schering Plough, Sumitomo Dainippon Pharma, Sunovion Takeda, Diaz Caneja Grant / Research support from: Exeltis Angelini